Right. If the CVR payout on just the approval with the OS label alone is around $7.40, I can't see any reason why he would take anything less than this. The $7.40 doesn't even take into consideration any of the future royalties due; and, it's pretty clear to me that this will be the new SOC - further, melanoma and other cancers will put this well over a $1 billion drug (of which CVRs payout above $1B)
News 
Market Data 
Discover 
